PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.\', \'INSERM, Centre d\'Investigation Clinique, CIC 1414, Rennes, F-35000, France.\', \'Aix-Marseille University, APHM, UMR \'Emergence des Pathologies Virales\' Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.\', \'Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.\', \'UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.\', \'Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d\'Angers, Angers, 49100, France.\', \'Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.\', \'Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.\', \'Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200, France.\', \'Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000, France.\', \'Pharmacy, Croix-Rousse Hospital, Lyon, 69005, France.\', \'ISPB, University Lyon 1, Lyon, 69005, France.\', \'Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044, France.\', \'Université de Tours, Tours, F-37044, France.\', \'INSERM, IPPRITT, U1248, Limoges, F-87000, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/fcp.12586
?:doi
?:hasPublicationType
?:journal
  • Fundamental & clinical pharmacology
is ?:pmid of
?:pmid
?:pmid
  • 32603486
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32603486>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32603486>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all